Saad Z. Usmani

39.2k citations

404 papers · 7.7k indexed · 5 hit papers · h-index 45

Hematology top 0.05%
- Multiple Myeloma Research and Treatments 327
Oncology top 0.5%
- Peptidase Inhibition and Analysis 73
- CAR-T cell therapy research 61
- Cancer Treatment and Pharmacology 47
Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 58
Molecular Biology top 1%
- Protein Degradation and Inhibitors 124
- Cancer therapeutics and mechanisms 18
Immunology top 5%
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 40

Co-authors: Niels W.C.J. van de Donk Ajai Chari Bart Barlogie Peter M. Voorhees Frits van Rhee Sarah Waheed John Crowley María‐Victoria Mateos
Cited by: Hematology Oncology Genetics
Journals: The Lancet (1 paper)Journal of Clinical Oncology (66 papers)SHILAP Revista de lepidopterología (5 papers)
Partner nations: United States Spain France

In The Last Decade

Saad Z. Usmani

373 papers receiving 7.6k citations

Hit Papers

5 papers align trajectories log scale

Peers

Countries citing papers authored by Saad Z. Usmani

Since Specialization

Citations

This map shows the geographic impact of Saad Z. Usmani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saad Z. Usmani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saad Z. Usmani more than expected).

Fields of papers citing papers by Saad Z. Usmani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Saad Z. Usmani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saad Z. Usmani. The network helps show where Saad Z. Usmani may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Saad Z. Usmani, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Saad Z. Usmani Line = papers co-authored together Saad Z. Usmani links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma Clinical Cancer Research ·Dickran Kazandjian,Benjamin Diamond,Marios Papadimitriou,Elizabeth Hill,Romanos Sklavenitis‐Pistofidis,Bachisio Ziccheddu,Patrick Blaney,Monika Chojnacka,Michael Durante,Kylee Maclachlan,Ryan M. Young,Saad Z. Usmani,Faith E. Davies,Gad Getz,Irene M. Ghobrial,Neha Korde,Gareth J. Morgan,Francesco Maura,Ola Landgren	2024	5
2	Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM). Journal of Clinical Oncology ·Cyrille Touzeau,Meral Beksaç,Evangelos Terpos,Saad Z. Usmani,Amrita Krishnan,Inger S. Nijhof,Wojciech Janowski,Cyrille Hulin,Sebastian Grosicki,Michel Delforge,Dana McAleer,Sarah Nagle,Yunsi Olyslager,Jonathan Miller,Zoe Craig,Jamal Nasir Khan,Tobias Kampfenkel,Salomon Manier,Niels W.C.J. van de Donk	2024	7
3	Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study British Journal of Haematology ·Ajay K. Nooka,Jonathan L. Kaufman,César A. Rodríguez,Andrzej Jakubowiak,Yvonne A. Efebera,Brandi Reeves,Tanya M. Wildes,Sarah A. Holstein,Larry D. Anderson,Ashraf Badros,Leyla Shune,Ajai Chari,Huiling Pei,Annelore Cortoos,Sharmila Patel,Thomas S. Lin,Peter M. Voorhees,Saad Z. Usmani,Paul G. Richardson	2024	0
4	Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis Blood ·Rahul Banerjee,Rachael Sexton,Andrew J. Cowan,Aaron S. Rosenberg,Sikander Ailawadhi,S. Vincent Rajkumar,Shaji Kumar,Angela Dispenzieri,Sagar Lonial,B G M Durie,Paul G. Richardson,Saad Z. Usmani,Antje Hoering,Robert Z. Orlowski	2024	3
5	Aiming for the cure in myeloma: Putting our best foot forward Blood Reviews ·Noffar Bar,Ross Firestone,Saad Z. Usmani	2023	3
6	Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma Clinical Cancer Research ·Monika Chojnacka,Benjamin Diamond,Bachisio Ziccheddu,Even H. Rustad,Kylee Maclachlan,Marios Papadimitriou,Eileen M. Boyle,Patrick Blaney,Saad Z. Usmani,Gareth J. Morgan,Ola Landgren,Francesco Maura	2023	1
7	MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study Clinical Lymphoma Myeloma & Leukemia ·Saad Z. Usmani,Lionel Karlin,Lotfi Benboubker,Hareth Nahi,Jesús F. San Miguel,Danielle Trancucci,Keqin Qi,Tara Stephenson,Alfredo Perales‐Puchalt,Katherine Chastain,Ajai Chari	2023	2
8	Radiation in a New Era of Multiple Myeloma Management: Patterns of Utilization, Clinical, Radiologic, and Biochemical Outcomes, and Possible Genomic Correlates of Response International Journal of Radiation OncologyBiologyPhysics ·Alexandra Dreyfuss,Beatrice Fregonese,Jennifer Ma,Reith Sarkar,J. Lee,G. Cederquist,Harper Hubbeling,Kathryn R. Tringale,N. Ari Wijetunga,Saad Z. Usmani,Carla Hajj,Brandon S. Imber,Joachim Yahalom	2023	0
9	T-Cell Exhaustion Signature Predicts Early Relapse after Autologous Stem Cell Transplant for Multiple Myeloma: BMT CTN 0702 Secondary Immune Analysis Blood ·Nezar Mehanna,Andriy Derkach,Billel Gasmi,Theodora Anagnostou,Heather Landau,Oscar Lahoud,Michael Scordo,Gunjan L. Shah,Hani Hassoun,Kylee Maclachlan,Malin Hultcrantz,Neha Korde,Sham Mailankody,Urvi A. Shah,Carlyn Tan,Saad Z. Usmani,Sergio Giralt,Alexander M. Lesokhin,David J. Chung	2023	1
10	Overcoming Barriers to Autologous Stem Cell Transplantation in Multiple Myeloma: Recommendations from a Multidisciplinary Roundtable Discussion Transplantation and Cellular Therapy ·Qaiser Bashir,Marc Braunstein,Tondre Buck,Cynthia Chmielewski,Brittany Hartmann,Murali Janakiram,Marisa A. McMahon,Laura Romundstad,Lynn Steele,Saad Z. Usmani,Kimberly Zwibel,Mohamed A. Kharfan‐Dabaja	2023	7
11	An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma Blood Cancer Discovery ·Ross Firestone,Alexander M. Lesokhin,Saad Z. Usmani	2023	13
12	A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse Clinical Lymphoma Myeloma & Leukemia ·Manisha Bhutani,David Foureau,Myra Robinson,Fei Guo,Kateryna Fesenkova,Shebli Atrash,Barry Paul,Cindy Varga,Reed Friend,Mauricio Pineda‐Roman,Katherine Rigby,James T. Symanowski,Sarah Norek,Mallory R. Tucker,Lawrence J. Druhan,Peter M. Voorhees,Saad Z. Usmani	2023	2
13	Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations Blood Advances ·Kylee Maclachlan,Tina Bagratuni,Efstathios Kastritis,Bachisio Ziccheddu,Sydney X. Lu,Venkata Yellapantula,Chris Famulare,Kimon V. Argyropoulos,Andriy Derkach,Elli Papaemmanuil,Ahmet Doǧan,Alexander M. Lesokhin,Saad Z. Usmani,Ola Landgren,Lia Palomba,Francesco Maura,Meletios Α. Dimopoulos	2022	1
14	CARTITUDE-2: Phase 2 Multicohort Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma Transplantation and Cellular Therapy ·Hermann Einsele,Niels W.C.J. van de Donk,Bertrand Arnulf,Jordan M. Schecter,Kevin C. De Braganca,Helen Varsos,William Deraedt,Hong Tian,Martin Vogel,Marlene J. Carrasco-Alfonso,Muhammad Akram,Xiaoling Wu,Tonia Nesheiwat,María‐Victoria Mateos,Saad Z. Usmani	2021	0
15	Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma Current Medical Research and Opinion ·Tom Martin,Saad Z. Usmani,Jordan M. Schecter,Martin Vogel,Carolyn C. Jackson,William Deraedt,Hong Tian,Tzu‐Min Yeh,Arnob Banerjee,Lida Pacaud,Ashraf Garrett,Anja Haltner,Chris Cameron,Suzy Van Sanden,Joris Diels,Satish Valluri,Imtiaz A. Samjoo	2021	34
16	Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report Blood Cancer Journal ·David Murray,Noemí Puig,Sigurður Y. Kristinsson,Saad Z. Usmani,Angela Dispenzieri,Giada Bianchi,Shaji Kumar,Wee Joo Chng,Roman Hájek,Bruno Paiva,Anders Waage,S. Vincent Rajkumar,Brian G.M. Durie	2021	92
17	Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges Bone Marrow Transplantation ·Binod Dhakal,Parameswaran Hari,Saad Z. Usmani,Mehdi Hamadani	2020	23
18	Prognostic Significance of Ki67 Expression By Immunohistochemistry (IHC) on Bone Marrow Biopsy in Newly Diagnosed Multiple Myeloma Blood ·Myra Robinson,Shebli Atrash,Taylor Brown,Jared Block,Edward H. Lipford,Elton T. Smith,Reed Friend,Amanda Aneralla,Alankrita Taneja,Qing Zhang,David Foureau,Chelsea Sprouse,Ami Ndiaye,James T. Symanowski,Belinda R. Avalos,Edward A. Copelan,Peter M. Voorhees,Saad Z. Usmani,Manisha Bhutani	2017	0
19	A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease Clinical Cancer Research ·Razelle Kurzrock,Peter M. Voorhees,Corey Casper,Richard R. Furman,Luis Fayad,Sagar Lonial,Hossein Borghaei,Sundar Jagannath,Lubomir Sokol,Saad Z. Usmani,Helgi van de Velde,Xiang Qin,Thomas A. Puchalski,Brett M. Hall,Manjula Reddy,Ming Qi,Frits van Rhee	2013	166
20	Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1 Clinical Cancer Research ·Christoph Heuck,Jackie Szymonifka,Emily Hansen,John D. Shaughnessy,Saad Z. Usmani,Frits van Rhee,Elias Anaissie,Bijay Nair,Sarah Waheed,Yazan Alsayed,Nathan Petty,Clyde Bailey,Joshua Epstein,Antje Hoering,John Crowley,Bart Barlogie	2012	13

About Saad Z. Usmani

Saad Z. Usmani is a scholar working on Hematology, Oncology and Genetics, having authored 404 papers that have together received 7.7k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (327 papers), Protein Degradation and Inhibitors (124 papers), Peptidase Inhibition and Analysis (73 papers), CAR-T cell therapy research (61 papers), Chronic Lymphocytic Leukemia Research (58 papers), Cancer Treatment and Pharmacology (47 papers), Monoclonal and Polyclonal Antibodies Research (40 papers) and Cancer therapeutics and mechanisms (18 papers). The work is most often cited by research in Hematology (5.9k citations), Oncology (4.4k citations) and Genetics (1.0k citations). Saad Z. Usmani has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Niels W.C.J. van de Donk, Ajai Chari, Bart Barlogie, Peter M. Voorhees, Frits van Rhee, Sarah Waheed, John Crowley, María‐Victoria Mateos, Antje Hoering and Manisha Bhutani. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact